Using engineered antibody fragments for imaging gliomas during immunotherapy
Engineered antibody fragments for PET imaging of immunotherapeutic targets in gliomas
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-10884221
This study is looking at a new way to use PET scans to see how well immunotherapy is working for people with gliomas, a type of brain tumor, so doctors can make better treatment choices for their patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10884221 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a non-invasive imaging technique using PET scans to monitor the effectiveness of immunotherapy in patients with gliomas, a type of brain tumor. By utilizing radiolabeled antibody fragments, the study aims to quantify specific immune cell markers that can indicate how well the treatment is working. The approach involves testing these imaging agents in mouse models that closely mimic human glioma conditions, with the goal of translating these findings to improve patient care. If successful, this method could help doctors make better treatment decisions for patients undergoing immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include both adults and children diagnosed with gliomas who are undergoing or considering immunotherapy.
Not a fit: Patients with gliomas who are not eligible for immunotherapy or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new way to monitor and improve immunotherapy outcomes for glioma patients.
How similar studies have performed: While the use of antibody fragments for imaging is a promising approach, this specific application in gliomas is still in the early stages and has not been widely tested.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOHANBASH, GARY — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: KOHANBASH, GARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology